Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 20404 | 400 | 22.2 | 59% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1692 | 6172 | FAMILYWISE ERROR RATE//MULTIPLE TESTING//FALSE DISCOVERY RATE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | NON INFERIORITY MARGIN | Author keyword | 24 | 82% | 4% | 14 |
| 2 | NON INFERIORITY | Author keyword | 18 | 24% | 17% | 66 |
| 3 | THREE ARM DESIGN | Author keyword | 17 | 100% | 2% | 8 |
| 4 | NONINFERIORITY MARGIN | Author keyword | 15 | 68% | 3% | 13 |
| 5 | ACTIVE CONTROL TRIALS | Author keyword | 12 | 86% | 2% | 6 |
| 6 | CONSTANCY ASSUMPTION | Author keyword | 12 | 86% | 2% | 6 |
| 7 | FIXED MARGIN METHOD | Author keyword | 11 | 100% | 2% | 6 |
| 8 | PUTATIVE PLACEBO | Author keyword | 8 | 100% | 1% | 5 |
| 9 | THREE ARM TRIAL | Author keyword | 6 | 80% | 1% | 4 |
| 10 | ACTIVE CONTROL TRIAL | Author keyword | 6 | 71% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | NON INFERIORITY MARGIN | 24 | 82% | 4% | 14 | Search NON+INFERIORITY+MARGIN | Search NON+INFERIORITY+MARGIN |
| 2 | NON INFERIORITY | 18 | 24% | 17% | 66 | Search NON+INFERIORITY | Search NON+INFERIORITY |
| 3 | THREE ARM DESIGN | 17 | 100% | 2% | 8 | Search THREE+ARM+DESIGN | Search THREE+ARM+DESIGN |
| 4 | NONINFERIORITY MARGIN | 15 | 68% | 3% | 13 | Search NONINFERIORITY+MARGIN | Search NONINFERIORITY+MARGIN |
| 5 | ACTIVE CONTROL TRIALS | 12 | 86% | 2% | 6 | Search ACTIVE+CONTROL+TRIALS | Search ACTIVE+CONTROL+TRIALS |
| 6 | CONSTANCY ASSUMPTION | 12 | 86% | 2% | 6 | Search CONSTANCY+ASSUMPTION | Search CONSTANCY+ASSUMPTION |
| 7 | FIXED MARGIN METHOD | 11 | 100% | 2% | 6 | Search FIXED+MARGIN+METHOD | Search FIXED+MARGIN+METHOD |
| 8 | PUTATIVE PLACEBO | 8 | 100% | 1% | 5 | Search PUTATIVE+PLACEBO | Search PUTATIVE+PLACEBO |
| 9 | THREE ARM TRIAL | 6 | 80% | 1% | 4 | Search THREE+ARM+TRIAL | Search THREE+ARM+TRIAL |
| 10 | ACTIVE CONTROL TRIAL | 6 | 71% | 1% | 5 | Search ACTIVE+CONTROL+TRIAL | Search ACTIVE+CONTROL+TRIAL |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NON INFERIORITY TRIALS | 41 | 61% | 11% | 43 |
| 2 | NONINFERIORITY TRIALS | 21 | 73% | 4% | 16 |
| 3 | ACTIVE CONTROL TRIALS | 12 | 26% | 10% | 40 |
| 4 | ACTIVE CONTROLLED TRIALS | 11 | 69% | 2% | 9 |
| 5 | EQUIVALENCE RANDOMIZED TRIALS | 10 | 44% | 5% | 18 |
| 6 | EQUIVALENCE TRIALS | 7 | 41% | 4% | 14 |
| 7 | ESTABLISHING EFFICACY | 6 | 80% | 1% | 4 |
| 8 | PLACEBO ARM | 6 | 71% | 1% | 5 |
| 9 | NON INFERIORITY | 6 | 13% | 11% | 43 |
| 10 | ASSESSING NON INFERIORITY | 6 | 100% | 1% | 4 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Through the looking glass: understanding non-inferiority | 2011 | 31 | 10 | 70% |
| How to Demonstrate Similarity by Using Noninferiority and Equivalence Statistical Testing in Radiology Research | 2013 | 18 | 29 | 17% |
| Methodology of superiority vs. equivalence trials and non-inferiority trials | 2007 | 46 | 18 | 44% |
| The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians | 2011 | 10 | 4 | 75% |
| Non-inferiority study design: lessons to be learned from cardiovascular trials | 2012 | 18 | 24 | 46% |
| Evaluating "superiority", "'equivalence" and "non-inferiority" in clinical trials | 2007 | 4 | 5 | 100% |
| Making sense of noninferiority: A clinical and statistical perspective on its application to cardiovascular clinical trials | 2007 | 14 | 28 | 54% |
| Issues on the selection of non-inferiority margin in clinical trials | 2009 | 4 | 17 | 71% |
| Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs | 2013 | 2 | 21 | 38% |
| Reviewing statistical analysis plans - A guide for medical writers | 2006 | 0 | 2 | 100% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PHARMACEUT LOGIST | 2 | 67% | 0.5% | 2 |
| 2 | OPASS | 2 | 50% | 0.8% | 3 |
| 3 | BIOMETR 1 | 2 | 18% | 2.5% | 10 |
| 4 | OBOPASS | 1 | 100% | 0.5% | 2 |
| 5 | BIOMETR 6 | 1 | 20% | 1.5% | 6 |
| 6 | BIOMETR 2 | 1 | 23% | 1.3% | 5 |
| 7 | OB OTS CDER | 1 | 30% | 0.8% | 3 |
| 8 | EPIDEMIOL SURVEILLANCE UNIT EPI | 1 | 33% | 0.5% | 2 |
| 9 | QUANTITAT METHODS INFORMAT SCI | 1 | 33% | 0.5% | 2 |
| 10 | HTA UNIT | 1 | 16% | 1.0% | 4 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000193050 | UNCONDITIONAL TEST//2 X 2 TABLES//AGRESTI COULL INTERVAL |
| 2 | 0.0000177590 | BRIDGING STUDY//MULTIREGIONAL CLINICAL TRIAL//MULTIREGIONAL TRIAL |
| 3 | 0.0000173911 | INDIVIDUAL BIOEQUIVALENCE//HIGHLY VARIABLE DRUGS//BIOEQUIVALENCE |
| 4 | 0.0000106099 | CONDITIONAL POWER//INTERIM ANALYSIS//SAMPLE SIZE RE ESTIMATION |
| 5 | 0.0000084606 | EQUIPOISE//SHAM SURGERY//DEVELOPING WORLD BIOETHICS |
| 6 | 0.0000075398 | FALSE DISCOVERY RATE//MULTIPLE TESTING//FAMILYWISE ERROR RATE |
| 7 | 0.0000073451 | PARALLEL LINE BIOASSAY//SLOPE RATIO BIOASSAY//FIELLER METHOD |
| 8 | 0.0000072308 | CONSORT//OTTAWA METHODS//REPORTING QUALITY |
| 9 | 0.0000065319 | PLACEBO ANALGESIA//NOCEBO//PLACEBO |
| 10 | 0.0000057287 | BIOSTATISTICS KNOWLEDGE//AQUACULTURE RESEARCH//BASELINE COMPARISONS |